AN2 Therapeutics Inc (NASDAQ: ANTX) kicked off on Friday, up 8.94% from the previous trading day, before settling in for the closing price of $1.23. Over the past 52 weeks, ANTX has traded in a range of $0.87-$22.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 37.08%. With a float of $21.36 million, this company’s outstanding shares have now reached $29.74 million.
Considering the fact that the conglomerate employs 41 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 50.0%, operating margin of -83756.25%, and the pretax margin is -75871.25%.
AN2 Therapeutics Inc (ANTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of AN2 Therapeutics Inc is 28.42%, while institutional ownership is 40.07%. The most recent insider transaction that took place on Nov 19 ’24, was worth 155,258. In this transaction Director of this company bought 150,000 shares at a rate of $1.04, taking the stock ownership to the 560,073 shares. Before that another transaction happened on Nov 20 ’24, when Company’s Director bought 50,000 for $1.16, making the entire transaction worth $57,870. This insider now owns 585,073 shares in total.
AN2 Therapeutics Inc (ANTX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 37.08% per share during the next fiscal year.
AN2 Therapeutics Inc (NASDAQ: ANTX) Trading Performance Indicators
Take a look at AN2 Therapeutics Inc’s (ANTX) current performance indicators. Last quarter, stock had a quick ratio of 9.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.14 in one year’s time.
Technical Analysis of AN2 Therapeutics Inc (ANTX)
Compared to the last year’s volume of 0.44 million, its volume of 2.68 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 73.13%. Additionally, its Average True Range was 0.08.
During the past 100 days, AN2 Therapeutics Inc’s (ANTX) raw stochastic average was set at 21.36%, which indicates a significant decrease from 75.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.55% in the past 14 days, which was lower than the 159.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0731, while its 200-day Moving Average is $2.1491. Nevertheless, the first resistance level for the watch stands at $1.4196 in the near term. At $1.4992, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.5790. If the price goes on to break the first support level at $1.2602, it is likely to go to the next support level at $1.1804. Now, if the price goes above the second support level, the third support stands at $1.1008.
AN2 Therapeutics Inc (NASDAQ: ANTX) Key Stats
The company with the Market Capitalisation of 43.62 million has total of 29,879K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -64,730 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -12,750 K.
